Exogenous interleukin-33 promotes hepatocellular carcinoma growth by remodelling the tumour microenvironment

[1]  Yan Yu,et al.  The IL-33/ST2 pathway suppresses murine colon cancer growth and metastasis by upregulating CD40 L signaling. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  Xiang Chen,et al.  Targeting Myeloid-Derived Suppressor Cells Is a Novel Strategy for Anti-Psoriasis Therapy , 2020, Mediators of inflammation.

[3]  Hai Li,et al.  ST2 silencing aggravates ventricular remodeling and chronic heart failure in rats by mediating the IL‐33/ST2 axis , 2020, Journal of tissue engineering and regenerative medicine.

[4]  C. Brightling,et al.  ST2 expression and release by the bronchial epithelium is downregulated in asthma , 2020, Allergy.

[5]  Chenyu Zhang,et al.  Pro-inflammatory TNF-α and IFN-γ Promote Tumor Growth and Metastasis via Induction of MACC1 , 2020, Frontiers in Immunology.

[6]  G. Sandusky,et al.  ST2 as checkpoint target for colorectal cancer immunotherapy. , 2020, JCI insight.

[7]  Jiandie D. Lin,et al.  The obesity-induced adipokine sST2 exacerbates adipose Treg and ILC2 depletion and promotes insulin resistance , 2020, Science Advances.

[8]  M. Feldmann,et al.  Identification of TNFR2 and IL-33 as therapeutic targets in localized fibrosis , 2019, Science Advances.

[9]  M. Hibbs,et al.  IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization , 2019, Nature Communications.

[10]  Yueyong Li,et al.  Genetic variants in IL-33/ST2 pathway with the susceptibility to hepatocellular carcinoma in a Chinese population. , 2019, Cytokine.

[11]  J. Soh,et al.  Critical role of the MCAM-ETV4 axis triggered by extracellular S100A8/A9 in breast cancer aggressiveness , 2019, Neoplasia.

[12]  C. Bachert,et al.  Protease/antiprotease network in allergy: The role of Staphylococcus aureus protease‐like proteins , 2019, Allergy.

[13]  L. Tu,et al.  IL-33 at the Crossroads of Metabolic Disorders and Immunity , 2019, Front. Endocrinol..

[14]  Guo‐Jun Zhang,et al.  Interleukin-33 in Malignancies: Friends or Foes? , 2018, Front. Immunol..

[15]  Guangbo Zhang,et al.  IL-33 Released in the Liver Inhibits Tumor Growth via Promotion of CD4+ and CD8+ T Cell Responses in Hepatocellular Carcinoma , 2018, The Journal of Immunology.

[16]  Wenchao Liu,et al.  Increased serum interleukin-33 concentrations predict worse prognosis of aneurysmal subarachnoid hemorrhage. , 2018, Clinica chimica acta; international journal of clinical chemistry.

[17]  J. Fournié,et al.  The Pro-tumorigenic IL-33 Involved in Antitumor Immunity: A Yin and Yang Cytokine , 2018, Front. Immunol..

[18]  K. M. Larsen,et al.  The Role of IL-33/ST2 Pathway in Tumorigenesis , 2018, International journal of molecular sciences.

[19]  W. Wang,et al.  IL-33 Initiates Vascular Remodelling in Hypoxic Pulmonary Hypertension by up-Regulating HIF-1α and VEGF Expression in Vascular Endothelial Cells , 2018, EBioMedicine.

[20]  Zhe Chen,et al.  Prognostic Significance of Serum Interleukins and Soluble ST2 in Traditional Chinese Medicine (TCM) Syndrome-Differentiated Rheumatoid Arthritis , 2018, Medical science monitor : international medical journal of experimental and clinical research.

[21]  D. Gabrilovich,et al.  Plasticity of myeloid-derived suppressor cells in cancer. , 2018, Current opinion in immunology.

[22]  S. Elahi,et al.  Prophylactic DNA vaccine targeting Foxp3+ regulatory T cells depletes myeloid-derived suppressor cells and improves anti-melanoma immune responses in a murine model , 2018, Cancer Immunology, Immunotherapy.

[23]  H. Kita,et al.  IL‐33: biological properties, functions, and roles in airway disease , 2017, Immunological reviews.

[24]  Kai Huang,et al.  IL33 Promotes Colon Cancer Cell Stemness via JNK Activation and Macrophage Recruitment. , 2017, Cancer research.

[25]  S. Paczesny,et al.  The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases , 2017, Front. Immunol..

[26]  Sapana N. Shah,et al.  IL‐33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis , 2017, Molecular carcinogenesis.

[27]  N. Zhang,et al.  Serum Levels of Soluble ST2 and IL-10 Are Associated with Disease Severity in Patients with IgA Nephropathy , 2016, Journal of immunology research.

[28]  T. Kuzel,et al.  Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia , 2016, Oncotarget.

[29]  Yan Li,et al.  Nasal administration of interleukin‐33 induces airways angiogenesis and expression of multiple angiogenic factors in a murine asthma surrogate , 2016, Immunology.

[30]  N. Samani,et al.  The PDGF-BB-SOX7 axis-modulated IL-33 in pericytes and stromal cells promotes metastasis through tumour-associated macrophages , 2016, Nature Communications.

[31]  B. Lu,et al.  Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy , 2016, Journal of Molecular Medicine.

[32]  Kathleen R. Cho,et al.  Epigenetic silencing of Th1 type chemokines shapes tumor immunity and immunotherapy , 2015, Nature.

[33]  A. Teufel,et al.  Tumor‐infiltrating, interleukin‐33–producing effector‐memory CD8+ T cells in resected hepatocellular carcinoma prolong patient survival , 2015, Hepatology.

[34]  Y. Qi,et al.  Tumoral Expression of IL-33 Inhibits Tumor Growth and Modifies the Tumor Microenvironment through CD8+ T and NK Cells , 2015, The Journal of Immunology.

[35]  S. Flamant,et al.  BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients. , 2014, Cancer research.

[36]  N. Arsenijević,et al.  Interleukin‐33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells , 2014, International journal of cancer.

[37]  D. Weiner,et al.  Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. , 2014, Cancer research.

[38]  Yaoh-Shiang Lin,et al.  The paracrine effect of cancer‐associated fibroblast‐induced interleukin‐33 regulates the invasiveness of head and neck squamous cell carcinoma , 2013, The Journal of pathology.

[39]  Lianfeng Zhang,et al.  Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice. , 2013, Cancer letters.

[40]  G. Multhoff,et al.  Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells. , 2012, Cytokine.

[41]  V. Seshan,et al.  A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis , 2012, Cell.

[42]  S. Nakae,et al.  The Alarmin Interleukin-33 Drives Protective Antiviral CD8+ T Cell Responses , 2012, Science.

[43]  Xinchun Chen,et al.  IL‐33 synergizes with TCR and IL‐12 signaling to promote the effector function of CD8+ T cells , 2011, European journal of immunology.

[44]  S. Rosenberg,et al.  Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[45]  A. Bergeron,et al.  Characterisation of dendritic cell subsets in lung cancer micro-environments , 2006, European Respiratory Journal.

[46]  J Fernando Bazan,et al.  IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. , 2005, Immunity.

[47]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[48]  H. Edmondson,et al.  Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies , 1954, Cancer.

[49]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..